SHYNDEC(SH:600420) Ge Long Hui A P P·2026-01-12 09:16Core Viewpoint - The approval of additional specifications for injectable piperacillin sodium by the National Medical Products Administration is a significant development for the company, enhancing its product portfolio and market potential in the antibiotic segment [1] Group 1: Company Developments - The company's wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., received the approval notice for the supplemental application of injectable piperacillin sodium [1] - The approved specifications include 1.0g, with existing specifications of 0.5g and 2.0g also passing the consistency evaluation for generic drug quality and efficacy [1] - The cumulative R&D investment for the consistency evaluation of injectable piperacillin sodium is approximately RMB 6.12 million (unaudited) [1] Group 2: Market Insights - The estimated sales revenue for injectable piperacillin sodium in public medical institutions nationwide is approximately RMB 1.906 billion for 2024 [1] - Other companies that have passed or are deemed to have passed the consistency evaluation for injectable piperacillin sodium include Shandong Lukang Pharmaceutical Co., Ltd., Shandong Anxin Pharmaceutical Co., Ltd., and North China Pharmaceutical Group Weicheng Pharmaceutical Co., Ltd. [1]